German HTA likely to toughen path for orphan drugs, warns industry association
This article was originally published in SRA
Companies developing orphan drugs should prepare for changes to Germany's early benefit assessment system that could make staying on the market with a reasonable price tougher, warns the European Confederation of Pharmaceutical Entrepreneurs (Eucope)1.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.